{
  "docId": "019de074-a7a3-7510-9ab9-5e74cd7e6c44",
  "docSlug": "8c206fa848e149a61a796c5e8f53c9e1",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 37 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 12,
  "pageCount": 37,
  "prevPage": 11,
  "nextPage": 13,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 8,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-a7a3-7510-9ab9-5e74cd7e6c44/12",
  "deckHref": "/decks/019de074-a7a3-7510-9ab9-5e74cd7e6c44",
  "deckJsonHref": "/decks/019de074-a7a3-7510-9ab9-5e74cd7e6c44.json",
  "deckAnchorHref": "/decks/019de074-a7a3-7510-9ab9-5e74cd7e6c44#slide-12",
  "components": [
    {
      "bbox": {
        "h": 0.115,
        "w": 0.72,
        "x": 0.14,
        "y": 0.758
      },
      "kind": "callout",
      "text": "Pegtarviliase was Well Tolerated with Adverse Events Primarily Associated with Subcutaneous Route of Administration",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a236fe41-b682-4b5e-bc85-cc49229f95a3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.215,
        "w": 0.378,
        "x": 0.083,
        "y": 0.235
      },
      "kind": "list",
      "text": "Adverse events (AEs) associated with subcutaneous administration\nMajority of AE were Grade 1/2 injection site reactions (ISR) and hypersensitivity reactions (HSR)\nManaged with antihistamines, steroids",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c9a556da-e11e-43f8-ac8f-ffc0be0bc913",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.473,
        "w": 0.502,
        "x": 0.437,
        "y": 0.219
      },
      "kind": "table",
      "text": "Adverse Events | Participants N=13\nAny treatment-emergent AE | 13 (100%)\nAE leading to discontinuation | 0\nAE leading to dose reduction | 0\nAE of special interest: HSR | 2 (15.3%)\nISR | 10 (76.9%)\nSerious AEs | 1 (7.7%)\nFatal | 0\nRelated | 0",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "11e8d425-3c6d-413c-a487-0748dbdaf935",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.808,
        "x": 0.068,
        "y": 0.045
      },
      "kind": "title",
      "text": "Interim Results from Phase 1/2 Clinical Trial: Safety Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "22c0e11b-d2a5-4676-b15c-c79591c79bde",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 13,
      "from": 9,
      "beatId": "7c8dedf5-5b20-4ddd-bab4-25563ee26ac5",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The document presents Pegtarviliase as a solution to lower homocysteine levels",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    },
    {
      "to": 12,
      "from": 11,
      "beatId": "53315100-e2a8-4809-bf83-d6e3abc2c164",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Evidence and Proof",
      "beatSlug": "consultants-gambit-evidence-proof",
      "evidence": "The document presents interim results from the Phase 1/2 clinical trial",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}